Ibio vs Lyell Immunopharma
Ibio is the larger business, with $100,000 of revenue in fiscal 2026 against $36,000 for Lyell Immunopharma (2.8 times as much). Lyell Immunopharma grew faster (-41.0% against -75.0%). Ibio kept more of each dollar of sales as profit: a net margin of -33044.0% against -762355.6%. Ibio carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | IbioIBIO, 2026 | Lyell ImmunopharmaLYEL, 2025 |
|---|---|---|
| Revenue | $100,000 | $36,000 |
| Revenue growth | -75.0% | -41.0% |
| Net income | −$33.0m | −$274m |
| Operating margin | -35141.0% | -748344.4% |
| Net margin | -33044.0% | -762355.6% |
| Return on equity | -65.7% | -87.0% |
| Free cash flow | −$23.8m | −$151m |
| Cash | $56.4m | $60.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 23 | 161 |
| Market value | $45.5m | $252m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 4 buys, 0 sales | 2 buys, 29 sales |